Orbus Therapeutics

• Eflornithine

Sources: prnewswire.com

• Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

  Phase 1, Recruiting, 66 people, May 30, 2023

• NCT02796261

  Phase 3, Status unknown, 343 people, Jun 10, 2016

Sources: clinicaltrials.gov